Evidence map›Paper›PMID 39165834›Full record

ArticleFrontiers in cellular neuroscience2024

Neuroprotective and anti-inflammatory properties of proteins secreted by glial progenitor cells derived from human iPSCs.

Diana I Salikhova, Margarita O Shedenkova, Anastasya K Sudina, Ekaterina V Belousova, Irina A Krasilnikova, Anastasya A Nekrasova, Zlata A Nefedova, Daniil A Frolov, Timur Kh Fatkhudinov, Andrey V Makarov and 4 more

Abstract read
In one paragraph

Article in Frontiers in cellular neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Diana I SalikhovaLaboratory of Cellular Biotechnology, Research Institute of Molecular and Cellular Medicine, Medical Institute of RUDN University, Moscow, Russia.
Margarita O ShedenkovaLaboratory of Cellular Biotechnology, Research Institute of Molecular and Cellular Medicine, Medical Institute of RUDN University, Moscow, Russia.
Anastasya K SudinaLaboratory of Cellular Biotechnology, Research Institute of Molecular and Cellular Medicine, Medical Institute of RUDN University, Moscow, Russia.
Ekaterina V BelousovaLaboratory of Cellular Biotechnology, Research Institute of Molecular and Cellular Medicine, Medical Institute of RUDN University, Moscow, Russia.
Irina A KrasilnikovaMedical Genetic Center, National Medical Research Center for Children's Health, Moscow, Russia.
Anastasya A NekrasovaMedical Genetic Center, National Medical Research Center for Children's Health, Moscow, Russia.
Zlata A NefedovaI.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Daniil A FrolovInstitute of Information Technologies, MIREA-Russian Technological University, Moscow, Russia.
Timur Kh FatkhudinovLaboratory of Cellular Biotechnology, Research Institute of Molecular and Cellular Medicine, Medical Institute of RUDN University, Moscow, Russia.
Andrey V MakarovLaboratory of Cellular Biotechnology, Research Institute of Molecular and Cellular Medicine, Medical Institute of RUDN University, Moscow, Russia.
Alexander M SurinLaboratory of Fundamental and Applied Problems of Pain, Institute of General Pathology and Pathophysiology, Moscow, Russia.
Kirill V SavostyanovMedical Genetic Center, National Medical Research Center for Children's Health, Moscow, Russia.
Dmitry V GoldshteinLaboratory of Cellular Biotechnology, Research Institute of Molecular and Cellular Medicine, Medical Institute of RUDN University, Moscow, Russia.
Zanda V BakaevaMedical Genetic Center, National Medical Research Center for Children's Health, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, stem cells technology is an effective tool in regenerative medicine. Cell therapy is based on the use of stem/progenitor cells to repair or replace damaged tissues or organs. This approach can be used to treat various diseases, such as cardiovascular, neurological diseases, and injuries of various origins. The mechanisms of cell therapy therapeutic action are based on the integration of the graft into the damaged tissue (replacement effect) and the ability of cells to secrete biologically active molecules such as cytokines, growth factors and other signaling molecules that promote regeneration (paracrine effect). However, cell transplantation has a number of limitations due to cell transportation complexity and immune rejection. A potentially more effective therapy is using only paracrine factors released by stem cells. Secreted factors can positively affect the damaged tissue: promote forming new blood vessels, stimulate cell proliferation, and reduce inflammation and apoptosis. In this work, we have studied the anti-inflammatory and neuroprotective effects of proteins with a molecular weight below 100 kDa secreted by glial progenitor cells obtained from human induced pluripotent stem cells. Proteins secreted by glial progenitor cells exerted anti-inflammatory effects in a primary glial culture model of LPS-induced inflammation by reducing nitric oxide (NO) production through inhibition of inducible NO synthase (iNOS). At the same time, added secreted proteins neutralized the effect of glutamate, increasing the number of viable neurons to control values. This effect is a result of decreased level of intracellular calcium, which, at elevated concentrations, triggers apoptotic death of neurons. In addition, secreted proteins reduce mitochondrial depolarization caused by glutamate excitotoxicity and help maintain higher NADH levels. This therapy can be successfully introduced into clinical practice after additional preclinical studies, increasing the effectiveness of rehabilitation of patients with neurological diseases.

Indexed as

glial progenitor cellsglutamate excitotoxicityhuman induced pluripotent stem cellsLPS-induced inflammationsecreted proteins

Identifiers

PMID39165834
PMCPMC11333358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.